Treating moderate mitral regurgitation in heart surgery patients
Treatments studied
Part of Heart & circulation clinical trials.
This trial looks at how to treat moderate mitral regurgitation (a leaky heart valve) in people who are already having coronary artery bypass surgery (CABG). It aims to find the best way to manage this condition to improve heart function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled to have coronary artery bypass graft (CABG) surgery.
- You have moderate mitral regurgitation (a moderate leak in the valve between your left heart chambers), confirmed by two separate heart ultrasound tests.
- You do not have low blood pressure (below 100 mm Hg) or symptoms of low blood pressure.
- Your kidney function is good (estimated GFR of 30 ml/min or higher).
- You are not allergic or had bad reactions to ACE inhibitors or ARBs (common blood pressure medicines).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an “epicardial” device placed during planned heart surgery to reduce mitral valve leaking (“mitral regurgitation”). If you have moderate-to-severe valve leak from ischemic heart disease and are already scheduled for heart surgery, this may help improve how well the valve works.
This trial focuses on people with severe mitral valve narrowing or leaking who still have symptoms even after the best usual medications. It may help find better care and measure health outcomes when surgery is judged too risky or not suitable.
This trial tests a new device called the SATURN system, which places a new mitral valve without open-heart surgery. It is for people aged 65 and older with severe mitral regurgitation who are at high risk for surgery.
This trial tests a new device designed to fix a leaky mitral valve in people with heart failure. It may help you breathe easier and feel less tired if your valve leak is severe and medicines have not been enough.
This trial studies a minimally invasive mitral valve repair/replacement approach for people with severe mitral regurgitation (leaky mitral valve) who are not good candidates for standard surgery or catheter options. It may help improve symptoms by treating the leaky valve when other treatments aren’t suitable.
This trial compares two blood-pressure and heart-failure medicines: sacubitril/valsartan versus ramipril, to see which improves heart pumping and heart structure over time. It’s aimed at people with ischemic (blocked-artery) heart failure with mid-range ejection fraction and ongoing symptoms.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.